npj Breast Cancer (Apr 2023)
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
- Emma Zattarin,
- Daniele Presti,
- Luigi Mariani,
- Caterina Sposetti,
- Rita Leporati,
- Alice Menichetti,
- Chiara Corti,
- Chiara Benvenuti,
- Giovanni Fucà,
- Riccardo Lobefaro,
- Francesca Ligorio,
- Leonardo Provenzano,
- Andrea Vingiani,
- Marta Del Vecchio,
- Gaia Griguolo,
- Marianna Sirico,
- Ottavia Bernocchi,
- Antonio Marra,
- Paola Zagami,
- Elisa Agostinetto,
- Flavia Jacobs,
- Pierluigi Di Mauro,
- Andrea Esposito,
- Carlo Alberto Giorgi,
- Luca Lalli,
- Laura Boldrini,
- Pier Paolo Berton Giacchetti,
- Ambra Carnevale Schianca,
- Valentina Guarneri,
- Rebecca Pedersini,
- Agnese Losurdo,
- Alberto Zambelli,
- Daniele Generali,
- Carmen Criscitiello,
- Giuseppe Curigliano,
- Giancarlo Pruneri,
- Filippo de Braud,
- Maria Vittoria Dieci,
- Claudio Vernieri
Affiliations
- Emma Zattarin
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
- Daniele Presti
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
- Luigi Mariani
- Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori
- Caterina Sposetti
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
- Rita Leporati
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
- Alice Menichetti
- Oncology 2, Istituto Oncologico Veneto IOV - IRCCS
- Chiara Corti
- Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS
- Chiara Benvenuti
- IRCCS Humanitas Research Hospital
- Giovanni Fucà
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
- Riccardo Lobefaro
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
- Francesca Ligorio
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
- Leonardo Provenzano
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
- Andrea Vingiani
- Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori
- Marta Del Vecchio
- Division of Pharmacy, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori
- Gaia Griguolo
- Oncology 2, Istituto Oncologico Veneto IOV - IRCCS
- Marianna Sirico
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”
- Ottavia Bernocchi
- Farmacia Ospedaliera ASST Cremona
- Antonio Marra
- Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS
- Paola Zagami
- Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS
- Elisa Agostinetto
- IRCCS Humanitas Research Hospital
- Flavia Jacobs
- IRCCS Humanitas Research Hospital
- Pierluigi Di Mauro
- Medical Oncology Unit, ASST Spedali Civili
- Andrea Esposito
- Medical Oncology Unit, ASST Spedali Civili
- Carlo Alberto Giorgi
- Oncology 2, Istituto Oncologico Veneto IOV - IRCCS
- Luca Lalli
- Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori
- Laura Boldrini
- Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS
- Pier Paolo Berton Giacchetti
- Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS
- Ambra Carnevale Schianca
- Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS
- Valentina Guarneri
- Oncology 2, Istituto Oncologico Veneto IOV - IRCCS
- Rebecca Pedersini
- Medical Oncology Unit, ASST Spedali Civili
- Agnese Losurdo
- IRCCS Humanitas Research Hospital
- Alberto Zambelli
- IRCCS Humanitas Research Hospital
- Daniele Generali
- Breast Cancer Unit & Translational Research Unit, ASST Cremona
- Carmen Criscitiello
- Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS
- Giuseppe Curigliano
- Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS
- Giancarlo Pruneri
- Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori
- Filippo de Braud
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
- Maria Vittoria Dieci
- Oncology 2, Istituto Oncologico Veneto IOV - IRCCS
- Claudio Vernieri
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
- DOI
- https://doi.org/10.1038/s41523-023-00534-1
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 5
Abstract
Abstract Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.
